Acceleron Pharma Inc (XLRN) Stake Lowered by Axa

AXA trimmed its stake in shares of Acceleron Pharma Inc (NASDAQ:XLRN) by 16.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 269,092 shares of the biopharmaceutical company’s stock after selling 54,463 shares during the quarter. AXA owned about 0.59% of Acceleron Pharma worth $10,043,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Perceptive Advisors LLC lifted its holdings in shares of Acceleron Pharma by 127.2% in the 3rd quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after buying an additional 905,000 shares during the period. Westfield Capital Management Co. LP lifted its holdings in shares of Acceleron Pharma by 46.6% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock valued at $51,127,000 after buying an additional 534,440 shares during the period. Sectoral Asset Management Inc lifted its holdings in shares of Acceleron Pharma by 378.2% in the 2nd quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after buying an additional 478,099 shares during the period. BlackRock Inc. lifted its holdings in shares of Acceleron Pharma by 9.0% in the 2nd quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after buying an additional 330,635 shares during the period. Finally, UBS Asset Management Americas Inc. acquired a new stake in shares of Acceleron Pharma in the 2nd quarter valued at approximately $9,747,000. 85.70% of the stock is owned by institutional investors.

Shares of Acceleron Pharma Inc (NASDAQ:XLRN) traded up $1.21 during mid-day trading on Friday, reaching $45.12. The company had a trading volume of 666,831 shares, compared to its average volume of 319,504. The firm has a market capitalization of $1,986.27, a PE ratio of -17.42 and a beta of 1.59. Acceleron Pharma Inc has a 52-week low of $23.07 and a 52-week high of $45.52.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.02. The firm had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. Acceleron Pharma’s revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.55) earnings per share. research analysts forecast that Acceleron Pharma Inc will post -2.65 EPS for the current fiscal year.

XLRN has been the subject of several recent analyst reports. Barclays raised their price target on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, September 20th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a report on Wednesday, September 20th. ValuEngine cut Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. HC Wainwright initiated coverage on Acceleron Pharma in a report on Thursday, October 12th. They issued a “buy” rating and a $57.00 price target for the company. Finally, Royal Bank of Canada reissued a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $44.56.

In other Acceleron Pharma news, CFO Kevin F. Mclaughlin sold 4,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $42.42, for a total transaction of $169,680.00. Following the completion of the transaction, the chief financial officer now owns 45,300 shares of the company’s stock, valued at $1,921,626. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin F. Mclaughlin sold 19,000 shares of the firm’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $42.89, for a total value of $814,910.00. Following the transaction, the chief financial officer now directly owns 45,300 shares of the company’s stock, valued at approximately $1,942,917. The disclosure for this sale can be found here. Insiders have sold 135,021 shares of company stock valued at $5,034,598 in the last three months. 3.90% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Acceleron Pharma Inc (XLRN) Stake Lowered by Axa” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/01/13/axa-decreases-position-in-acceleron-pharma-inc-xlrn-updated-updated.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply